Tenofovir Alafenamide

• TARGET-EBV in MS: Targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate in multiple sclerosis Pending
  2025-522140-40-00 Phase II 1 country Oslo University Hospital HF
• The DELTA-EBV study Pending
  2025-522781-77-01 Phase II 1 country Helse Bergen HF
• A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-inj… Recruiting
  2023-508996-35-00 Phase II 7 countries Novartis Pharma AG
• An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan… Recruiting
  2024-515280-60-00 Phase III 5 countries Novartis Pharma AG
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting
  2023-505929-14-00 Phase III 11 countries Novartis Pharma AG
• Observational Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Patients with Chronic hepatitis D Recruiting
  2023-504414-29-00 Phase III/IV 1 country Karolinska University Hospital
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND-… Ended
  2024-514047-28-00 Phase III 4 countries Gilead Sciences Inc.
• Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Ended
  2024-511016-25-00 Phase II 1 country Antwerp University Hospital
• A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab … Ended
  2024-511933-36-00 Phase II 10 countries Novartis Pharma AG
• A phase 2a, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of RBD1016 in participants with chronic hepatitis D viru… Ended
  2023-509007-33-00 Phase II 1 country Ribocure Pharmaceuticals AB
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended
  2022-502966-26-01 Phase III 16 countries Novartis Pharma AG
• Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended
  2023-508499-12-00 Phase III 4 countries Novartis Pharma AG
• Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended
  2023-508498-97-00 Phase III 7 countries Novartis Pharma AG
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended
  2023-508559-37-00 Phase III 9 countries Novartis Pharma AG
• ANRS HB07 IP-Cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC d… Ended
  2024-515739-32-00 Phase II 4 countries ANRS Maladies Infectieuses Emergentes
• Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection Halted
  2023-506143-42-00 Phase II 1 country Gilead Sciences Inc.
• The TAF-MS study Ended
  2023-503814-62-00 Phase II 1 country Helse Bergen HF
• Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships with Clinical Assessments Ended
  2023-508957-24-00 Phase II 1 country Novartis Pharma AG
• A Clinical Study to Investigate the Efficacy and Safety of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-infected with Hepatitis B … Ended
  2023-506763-33-00 Phase II 3 countries Janssen - Cilag International

Showing 1–19 of 19 trials